GE Healthcare wins FDA nod for "breakthrough" FlightPlan for Liver

November 27, 2012 by MassDevice staff

Healthcare giant GE Healthcare (NYSE:GE) won FDA 510(k) clearance for its liver embolization imaging technology, FlightPlan for Liver.

The system has been on the market in Europe, Latin America and Asia since last year and has already been installed in 10 countries, GE reported.

Sign up to get our free newsletters delivered right to your inbox.

FlightPlan for Liver helps plan liver embolization interventions by providing an "3D road-map" of the vessels that lead to a lesion, helping the physician guide a catheter to a target artery, according to a press release.

The process of identifying blood vessels that feed a liver tumor can be time-consuming and existing solutions can require significant amounts of radiation and contrast media.

The GE technology aims to make the intricate and often difficult process of preparing a liver embolization simpler.

"With FlightPlan for Liver, interventionalists can gain confidence in identifying tumor-feeding vessels and be more selective when planning liver embolization," GE Healthcare premium angiography, detection & guidance solutions general manager Chantal Le Chat said in prepared remarks.

GE shares were down 0.4% to $20.95 as of about 1:45 p.m. today.

Permalink